AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group
December 12, 2018 08:00 ET
|
AzurRx BioPharma, Inc.
NEW YORK, Dec. 12, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...